The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease

Endokrynologia Polska

Volumn 61, Issue 6, 2010, Pages 683-690

  Krysiak, Robert ^a   Sierant, Marian ^a   Marek, Bogdan ^a,b   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Third Provincial Hospital   (Poland)

Author keywords

Coronary artery disease; Enalapril; Insulin resistance; Perindopril; Resistin

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PERINDOPRIL; RESISTIN;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; ENALAPRIL; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PERINDOPRIL; RESISTIN;

EID: 78650027925     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ahima RS, Osei SY. Adipokines in obesity. Front Horm Res 2008; 36: 182-197.
2. Calabro P, Yeh ET. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep 2008; 10: 32-38.
3. Krysiak R, Okopień B, Herman ZS. Adipose tissue: a new endocrine organ. Przegl Lek 2005; 62: 919-923.
4. Koh KK, Quon MJ, Han SH et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010; 140: 73-81.
5. Masuo K, Mikami H, Ogihara T et al. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001; 14: 530-538. (Pubitemid 32506726)
6. Huang SS, Wu TC, Lin SJ et al. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J 2009; 73: 2282-2287.
7. Yenicesu M, Yilmaz MI, Caglar K et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: c115-c121.
8. Yilmaz MI, Sonmez A, Caglar K et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147-153. (Pubitemid 46426854)
9. Amador N, Pérez-Luque E, Malacara JM et al. Leptin and heart sympathetic activity in normotensive obese and non-obese subjects. Ital Heart J 2004; 5: 29-35.
10. Ficek J, Kokot F, Chudek J et al. Influence of antihypertensive treatment with perindopril, pindolol or felodipinon plasma leptin concentration in patients with essential hypertension. Horm Metab Res 2002; 34: 703-708.
11. Piecha G, Adamczak M, Chudek J et al. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res 2007; 30: 187-194. (Pubitemid 46976037)
12. Delles C, Raff U, Mimran A et al. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008; 21: 1330-1336.
13. Steppan CM, Bailey ST, Bhat S et al.The hormone resistin links obesity to diabetes.Nature 2001; 409: 307-312.
14. Bokarewa M, Nagaev I, Dahlberg L et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795. (Pubitemid 40593223)
15. Savage DB, Sewter CP, Klenk ES et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202.
16. Patel L, Buckels AC, Kinghorn IJ et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-476.
17. Gualillo O, González-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007; 17: 275-283. (Pubitemid 350087698)
18. Ghosh S, Singh AK, Aruna B et al. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 2003; 305: 27-34. (Pubitemid 36197863)
19. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-447.
20. Norata GD, Ongari M, Garlaschelli K et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156: 279-284. (Pubitemid 46554524)
21. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans.J Clin Endocrinol Metab 2003; 88: 5452-5455.
22. Farvid MS, Ng TW, Chan DC et al. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 2005; 7: 406-413.
23. Utzschneider KM, Carr DB, Tong J et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48: 2330-2333.
24. Yaturu S, Reddy RD, Rains J et al. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine 2007; 37: 1-5. (Pubitemid 46575280)
25. Karmiris K, Koutroubakis IE, Xidakis C et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 100-105.
26. Takeishi Y, Niizeki T, Arimoto T et al. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ J 2007; 71: 460-464.
27. Koh KK, Quon MJ, Han SH et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010; 140: 73-81.
28. Derosa G, Fogari E, D'Angelo A et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261-268. (Pubitemid 46699517)
29. Krysiak R, Okopień B. Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep 2008; 60: 514-523.
30. Krysiak R, Łabuzek K, Okopień B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep 2009; 61: 1134-1145.
31. Lubos E, Messow CM, Schnabel R et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007; 193: 121-128.
32. Norata GD, Ongari M, Garlaschelli K et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156: 279-284. (Pubitemid 46554524)
33. Del Prato S. Measurement of insulin resistance in vivo. Drugs 1999; 58 (Suppl. 1): 3-6.
34. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-534.
35. Milicevic Z, Raz I, Beattie SD et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008; 31 (Suppl. 2): S155-S160.
36. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
37. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
38. McFarlane SI. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. Expert Rev Cardiovasc Ther 2009; 7: 1363-1371.
39. Abuissa H, O'Keefe J Jr. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab 2008; 10: 1157-1166.